Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治疗相关副作用是，但严重到足以停药程度是罕。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴受体激动剂临床应疗效性。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种巴巴激动剂，与第一代巴激动剂不同是没有麦角林结构。罗匹尼罗非麦角林结构可以说明其与巴D2受体有较高结合力。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治疗相关的副作用是常见的，但严重到足以停药的程度是罕见的。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴受体激动剂临床应疗效性。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似巴的巴激动剂，第一代巴激动剂不同的是没有麦角林结构。罗匹尼罗的非麦角林结构可以说明巴D2受体有较高的结合力。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性释放因子治疗相关的副作用是常见的，但严重到足以停药的程度是罕见的。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价受体动剂临床应疗效性。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似的动剂，与第一代动剂不同的是没有麦角林结构。罗匹尼罗的非麦角林结构可以说明其与D2受体有较高的结合力。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治疗相关副作用是常见，但严重到足以停药程度是罕见。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴受体激动剂临床应疗效性。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

匹是一种类似多巴多巴激动剂，与第一代多巴激动剂不同是没有麦角林结构。匹非麦角林结构可以说明其与多巴D2受体有较高结合力。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治疗相关的副作用是常见的，但严重到足以停药的程度是罕见的。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴受体激动剂临床应疗效性。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

尼是一种类似多巴的多巴激动剂，与第一代多巴激动剂不同的是没有麦角林结。尼的非麦角林结可以说明其与多巴D2受体有较高的结合力。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治疗相关的副作用的，但严重到足以停药的程度罕的。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价受体激动剂临床应疗效性。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗一种类的激动剂，与第一代激动剂不同的没有麦角林结构。罗匹尼罗的非麦角林结构可以说明其与D2受体有较高的结合力。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治疗相关副作用是常，严重到足以停药程度是罕。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴受体激动剂临床应疗效性。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一多巴多巴激动剂，与第一代多巴激动剂不同是没有麦角林结构。罗匹尼罗非麦角林结构可以说明其与多巴D2受体有较高结合力。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促腺激素释放因子治相关副作用是常见，但严重到足以停度是罕见。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴受体激动剂临床应。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似多巴多巴激动剂，与第一代多巴激动剂不同是没有麦角林结构。罗匹尼罗非麦角林结构可以说明其与多巴D2受体有较高结合力。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

促性腺激素释放因子治疗相关的副作用是常见的，但严重到足以停药的程度是罕见的。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴受体激动临床应疗效性。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似多巴的多巴激动，与第一代多巴激动的是没有麦角林结构。罗匹尼罗的非麦角林结构可以说明其与多巴D2受体有较高的结合力。